2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.07F.05 The Neutrophil/Lymphocyte Ratio Predict Lymph Node Metastasis in Patients with Clinical Stage T2 Non-Small Cell Lung Cancer.

EP.07F.05 The Neutrophil/Lymphocyte Ratio Predict Lymph Node Metastasis in Patients with Clinical Stage T2 Non-Small Cell Lung Cancer.

Back to course

Pdf Summary

The study titled "Neutrophil/lymphocyte ratio predicts lymph node metastasis in patients with clinical T2 non-small cell lung cancer" by Shinjiro Mizuguchi and colleagues from the Osaka City General Hospital investigates the potential of the neutrophil-lymphocyte ratio (NLR) as an indicator for lymph node metastasis in T2 non-small cell lung cancer (NSCLC) patients. The research analyzes data from 3662 lung cancer surgeries performed from 1994 to 2017, narrowing down to 1019 patients with tumors ranging from 3 cm to 5 cm.<br /><br />Exclusion criteria included patients with incomplete resections, without radical lymph node dissection, small cell carcinoma, and those lacking a blood examination within a month prior to surgery. This resulted in a focus group of 540 clinical T2 patients, comprising 365 males and 175 females, with a median age of 69.<br /><br />The study’s analysis involved various statistical methods, revealing that preoperative NLR could be used to predict lymph node metastasis. Specifically, an NLR cut-off value of 2.61 was identified as a critical threshold, with higher NLR values indicating a greater likelihood of metastatic nodes. This association was particularly pronounced when stratified by low C-reactive protein (CRP) levels.<br /><br />Findings suggest that NLR, as a marker of systemic inflammation, serves more effectively as a predictor for node-negative (pN0) rather than node-positive (pN1-3) metastasis in this patient subset. This offers increasing clinical value as an accessible, non-invasive prognostic tool ahead of surgical interventions.<br /><br />Future research directions include exploring NLR trends post-surgery to predict cancer recurrence, understanding the timing for optimal NLR measurement after resection, and determining whether NLR decreases following cancer resection. These insights can enhance individualized treatment strategies and potentially improve outcomes in NSCLC management.

Asset Subtitle

Shinjiro Mizuguchi

Meta Tag

Speaker Shinjiro Mizuguchi

Topic Early-Stage Non-small Cell Lung Cancer

Keywords

neutrophil-lymphocyte ratio

lymph node metastasis

T2 non-small cell lung cancer

NLR

systemic inflammation

clinical predictor

Osaka City General Hospital

cancer surgery

C-reactive protein

prognostic tool